Evicenter
MarkdownMedical informationP&T meetings
Deucrictibant (PHA121)

On-demand treatment of hereditary angioedema attacks

Also known as PHA-022121
Manufacturer
Pharvaris
Last updated
209 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of hereditary angioedema

Humanistic burden and health-related quality of life

21 evidence topics · 19 sources

Multinational adult survey: treatment exposure and quality-of-life outcomes
MeasureReported result
Participants included“260”
Participants using any long-term prophylaxis“153 (58.8%)”
First-line prophylaxis among prophylaxis users, per study classification“56/153 (36.6%)”
AE-QoL total score, mean ± SD“42.9 ± 23.2”
Participants with AE-QoL total score ≥39“137 of 260 (52.7%)”
Moderate to severe anxiety by HADS“69 (26.5%)”
Moderate to severe depression by HADS“27 (10.4%)”
Health-related quality of life during the last treated attack by time to on-demand treatment: US patient survey

“Patients with ≥1 HAE attack in the previous 3 months were recruited by the United States (US) HAE Association (HAEA) to complete an online survey.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A total of 94 respondents were included in the Treated Cohort, and 20 were included in the Untreated Cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the Treated Cohort, the mean (SD) EQ-5D-5L index score was 0.849 (0.2) “Today” and 0.568 (0.3) “During the last treated attack” (Fig. 1A), with the latter score indicative of substantial impairment in HRQoL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The mean (SD) index score was 0.667 (0.3) in patients who treated <1 h of attack onset and 0.504 (0.3) in those who treated 5 to < 8 h of attack onset (Fig. 1B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In terms of administration route, reductions in HRQoL and work productivity and increases in activity impairment were generally more pronounced among IV OD users than among SC OD users (mean EQ-5D-5L index score “During the last treated attack”: 0.480 vs 0.615).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Consistent with this, IV OD users took longer to administer treatment following attack onset than SC OD users (mean: 5.8 vs 2.8 h).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Funding for Outcomes Insights was provided by KalVista Pharmaceuticals (Cambridge, MA, USA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Burden of injectable on-demand treatment: US and UK patient and caregiver interviews
Carrying, delaying, and not treating attacks with on-demand treatment: US patient survey

“People living with HAE were recruited by the US Hereditary Angioedema Association (HAEA) to complete a 20-minute online survey between September 6, and October 19, 2022.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Respondents included 107 people with HAE, 80% female, 98% adults (≥ 18 years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Most patients (63.6%) reported that they did not carry on-demand treatment at all times when away from home.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The most common reason for not carrying on-demand treatment when away from home was ‘prefer to treat at home’ (72.1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Overall, 86% of respondents reported delaying on-demand treatment, despite recognizing the initial onset of an HAE attack and despite 97% of patients agreeing that it is important to recover quickly from an HAE attack.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“On average, one of every five (20%) HAE attacks are untreated (24% amongst on-demand only patients; 15% amongst prophylaxis patients).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This work was sponsored by KalVista Pharmaceuticals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Attacks, on-demand treatment, anxiety, and depression: multinational patient survey